Navigation Links
InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
Date:10/16/2008

erences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 14, 2008 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the uncertain, lengthy and expensive clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues; (ii) risks related to achieving positive clinical trial results; (iii) the results of the InterMune CAPACITY trials of pirfenidone may differ materially from those of the Shionogi & Co., Ltd. Phase 3 trial of pirfenidone in Japan; (iv) the designation of pirfenidone for Fast Track status by the FDA does not guarantee that the FDA will grant Priority Review of the NDA filed by InterMune in connection with the approval of pirfenidone for the treatment of IPF in the United States. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... ASA (OSE: ALGETA), the,cancer therapeutics company, announces ... the Tulane Cancer Center, New Orleans, has ... study of Alpharadin in men with,castration-resistant (also ... metastasized to the skeleton. , ... Prostate CAncer) study is a,double-blind, randomized, controlled ...
(Date:12/11/2009)... Dec. 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, ... announced the appointment of Dr. Alan Warrander to ... and Business Development. ,, "Dr. Warrander will be ... strategy for REOLYSIN(R)," said Dr. Brad Thompson, President ... on the design of a Phase 3 trial ...
(Date:12/10/2009)... -- Microban International, Ltd., the global leader ... with Sharp Imaging and Information Company of ... incorporate it,s third generation silver-based antimicrobial technology ... the calculator keys during manufacture, Microban ® ... damaging bacteria on the keys. ,, ...
(Date:12/10/2009)... Dec. 10 With the economy and markets ... Street,s largest, fastest-growing small cap equity research provider, will ... investment opportunities within the micro cap market at the ... January 11, 2010 at the Grand Hyatt Hotel in ... are overlooked and undervalued by much of Wall Street, ...
Breaking Biology Technology:Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3Microban Signs Exclusive Agreement with Sharp Electronics to Launch Calculators with New Microban(R) 3G Silver(TM) Antimicrobial Technology 2Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference 2
... announced,today that the Chicago Athenaeum Museum of Architecture ... for the new SoloSTAR(R) disposable,insulin injection pen for ... "LANTUS(R) SoloSTAR(R) and APIDRA(R) SoloSTAR(R), the results ... designed in dialogue with,patients, nurses and doctors and ...
... perfect complement to the power tie: a power shirt ... for soldiers in the field, hikers and others whose ... energy. , The February 14 issue of the journal ... zinc oxide nanowires can generate electrical current using the ...
... Investments in Dedicated Assets -, LIONVILLE, Pa., ... WST ) today announced that it has concluded ... manufacture and,assembly of components for the Exubera(R) inhalable ... October 2007 following Pfizer,Inc.,s decision to discontinue marketing ...
Other Biology Technology:Sanofi-aventis' SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award 2Sanofi-aventis' SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award 3Sanofi-aventis' SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award 4Sanofi-aventis' SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award 5Fiber-based nanotechnology in clothing could harvest energy from physical movement 2Fiber-based nanotechnology in clothing could harvest energy from physical movement 3Fiber-based nanotechnology in clothing could harvest energy from physical movement 4West Concludes Agreement with Nektar 2
(Date:12/14/2009)... University of Alberta researchers are part of an international ... not fossilized bones, to revise the history of North ... of U of A Earth and Atmospheric Sciences professor ... theory, based on radiocarbon dating of bones and teeth. ... large mammals in North America (the ,megafauna,) disappeared about ...
(Date:12/14/2009)... the Biomedical Engineering Society (BMES) have founded a new ... ). CVET is a forum for ... treatment. The first issue of the new quarterly ... other BMES publications at Springer, Annals of Biomedical ... , Cardiovascular Engineering and Technology will present ...
(Date:12/14/2009)... the United Nations Framework Convention on Climate Change ... hosted the ,Bend the Trend, event on Sunday ... and premiere the screening of the new ,Environmental ... Europe, a joint project of the European Environment ... ESA, is a series of short films showing ...
Breaking Biology News(10 mins):Biomedical Engineering Society's new journal to be published by Springer 2'Environmental Atlas of Europe' unveiled at COP15 2New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 1New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 2New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 3New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 4New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 5New From the Heinz Family Philanthropies 3A 10 Questions and Valuable Answers to Help Families If They Are Not Happy With Their Long Term Care 48581 6PharmaSURVEYORs Advanced Drug Safety Service Connects to Microsoft HealthVault 48576 1PharmaSURVEYORs Advanced Drug Safety Service Connects to Microsoft HealthVault 48576 2The Hidden Story 3A Poetry Inspired by Authors Struggle with Depression Addiction 48573 1The Hidden Story 3A Poetry Inspired by Authors Struggle with Depression Addiction 48573 2
... Blacksburg, Va. -- Innovative work on a new type ... professor of mechanical engineering at Virginia Tech, a National ... $400,000. , The focus of Goulbourne,s research is ... what happens to a human artery equipped with a ...
... Center have developed a risk prediction assessment for lung ... risk from chronic obstructive pulmonary disease (COPD), according to ... Cancer Prevention Research, a journal of the American ... analyzed data from 491 African Americans with lung cancer ...
... between Syracuse University and the Serum Institute of India ... children living in some of the most impoverished areas ... to a team of SU researchers led by Robert ... Arts and Sciences, to develop new oral vaccines against ...
Other Biology News:Goulbourne earns NSF award to research heart stent sensors 2Goulbourne earns NSF award to research heart stent sensors 3African-Americans have unique lung cancer risks from chronic obstructive pulmonary disease 2Syracuse University partners with Serum Institute of India to develop vaccines for children 2Syracuse University partners with Serum Institute of India to develop vaccines for children 3Syracuse University partners with Serum Institute of India to develop vaccines for children 4
Mouse P-Selectin/CD62P MAb (Clone 127933)...
Molecular Biological Resources has extensive abilities cloning and expression of prokaryotic and eukaryotic proteins. Please contact lloconne@molbiores.com to discuss your project. Contact lloconne@...
IgD Chain C (AMS 9.1)...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: